Globenewswire·2026-03-02 06:00Core Viewpoint - Sanofi's rilzabrutinib has received orphan drug designation in Japan for the treatment of IgG4-related disease, addressing a significant unmet medical need in this rare condition [1][7]. Group 1: Rilzabrutinib's Designation and Clinical Evaluation - The Ministry of Health, Labour and Welfare in Japan granted orphan drug designation to rilzabrutinib for IgG4-RD, highlighting the limited treatment options available for this rare disease [1]. - Rilzabrutinib was evaluated in a phase 2 study, showing a reduction in disease flares and other markers over 52 weeks, while minimizing the need for glucocorticoids [2]. - The safety profile of rilzabrutinib in the phase 2 study was consistent with previous studies, with no new safety signals observed [2]. Group 2: Broader Applications and Regulatory Status - Rilzabrutinib is being studied for multiple rare immune-mediated diseases and received approval for immune thrombocytopenia (ITP) in the US, EU, and UAE in 2025 [3]. - The drug is currently under regulatory review for ITP in Japan and has received expedited designations for various conditions, including IgG4-RD [3]. - Other than the approved ITP indications, the uses of rilzabrutinib for IgG4-RD and other conditions remain investigational [3]. Group 3: Mechanism and Potential Impact - Rilzabrutinib is a novel, oral, reversible covalent BTK inhibitor that aims to restore immune balance through multi-immune modulation [4]. - The drug targets BTK, which plays a critical role in immune-mediated disease processes, indicating its potential effectiveness in treating several rare diseases [4]. - The global prevalence of IgG4-RD is unknown due to its rarity and diagnostic challenges, emphasizing the need for effective treatments like rilzabrutinib [5]. Group 4: Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [6]. - The company is listed on EURONEXT: SAN and NASDAQ: SNY, indicating its presence in major financial markets [6].